Some genetic mutations that are expected to completely stop a gene from working surprisingly cause only mild or even no symptoms. Researchers in previous studies have discovered one reason why: cells ...

Arcturus Therapeutics (NASDAQ:ARCT) used a presentation at Guggenheim’s 2026 Emerging Outlook Biotech Summit to highlight ...

A new study from Whitehead Institute Member Jonathan Weissman reveals how cells may activate a compensation system that can, in some cases, reduce the effects of potentially harmful genetic mutations.

Seasonal flu + COVID vaccine: Currently, the Company's mRNA-1083 regulatory filing is under review in Europe and Canada. Moderna is awaiting further guidance from U.S. FDA on refiling the submission ...

Mount Sinai researchers have identified a cellular mechanism linking infections from influenza A viruses (IAVs) to cardiovascular disease, providing critical insights on how influenza can damage the ...

MRNA posts a narrower Q4 loss and beats sales estimates, despite a 30% revenue drop, while advancing its pipeline and ...

While the fabled fountain of youth may not actually exist, a new type of therapy now does.

RNA CAR T therapy Descartes‑08 targets BCMA‑positive plasma cells and delivers year‑long symptom relief in myasthenia gravis ...

Several leading medical groups in the U.S. urged a federal judge on Friday to bar the CDC from holding its next vaccine ...

With a shared purpose, we can realize the true promise of CRISPR and improve healthcare, providing hope to more patients with ...